regulatory safety update
FDA expanded HES safety warnings beyond the older RX box
The historical RX source emphasizes critically ill patients and sepsis. The FDA 2021 action additionally addresses surgical and blunt-trauma populations and availability of adequate alternatives.
What to reconcileRead the regulatory card before considering the historical product instructions. A lower dose or absence of sepsis does not establish renal safety. Confirm the current exact label and local policy.
2 source identities and dates
GlobalRPh RX List - HESPANGlobalRPh-hosted RX List | Source revision: March 2015
IV HESPAN 6% hetastarch in 0.9% saline; historical label mirror
Read this stored source FDA hydroxyethyl starch safety expansionFDA | Source revision: July 7, 2021 safety communication
Hydroxyethyl starch products including HESPAN; surgical/trauma safety context
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.8.
formulation strength limit
The requested lower starting amount may not fit this ER product
The VANTRELA ER renal instructions specify a reduced starting amount and direct another analgesic when the required dose is below the available minimum strength.
What to reconcileDo not split extended-release tablets to manufacture an unsupported strength or transfer another hydrocodone brand's instruction. Verify current product availability.
1 source identities and dates
GlobalRPh RX List - VANTRELA ERGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Oral VANTRELA ER hydrocodone tablets; not all hydrocodone formulations
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.8.
monitoring and measurement
Renal injury and laboratory or dialysis-device interference can coexist
The source describes genuine kidney injury, analyzer-dependent creatinine interference and false dialysis blood-leak alarms. These are separate problems and can occur in the same clinical episode.
What to reconcileNotify the laboratory and dialysis team and reassess the measurement method and device. Do not dismiss an apparent creatinine rise automatically or derive a renal antidote reduction from assay interference.
1 source identities and dates
GlobalRPh RX List - CYANOKITGlobalRPh-hosted RX List | Source revision: May 2021
IV hydroxocobalamin antidote for cyanide poisoning; not low-dose vitamin B12 replacement
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.8.
guideline vs label scope
KDIGO provides a lupus-nephritis reduction absent from the label table
The official label gives a qualitative reduction warning. KDIGO 2024 supplies a disease-specific indexed-eGFR reduction instruction; these differ in specificity rather than representing a universally applicable replacement label.
What to reconcileMatch lupus-nephritis context, starting exposure and retinal monitoring. Worsening renal function can also represent labeled drug toxicity, not only the underlying disease. Do not transfer the nephritis recommendation to malaria without review.
2 source identities and dates
PLAQUENIL - official renal precautionsDailyMed / ADVANZ PHARMA US | Source revision: October 2024
Oral PLAQUENIL hydroxychloroquine sulfate tablets; official product warnings
Read this stored source Hydroxychloroquine - lupus nephritis renal guidanceKDIGO | Source revision: 2024 lupus nephritis guideline
Hydroxychloroquine for SLE/lupus nephritis; guideline perspective
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.8.
population and formulation
The same 50% renal reduction starts from different adult and pediatric doses
SIKLOS provides separate pediatric and adult starting doses. The DROXIA extract is adult capsule guidance. Applying the adult starting amount to a child would change the regimen even if the percentage reduction were correct.
What to reconcileUse the exact age/product starting dose, prescribed weight method, measured CrCl instruction and hematology monitoring plan. Related hydroxyurea products remain separate.
1 source identities and dates
Hydroxyurea scored tablets - SIKLOSDailyMed / Medunik USA | Source revision: November 2023
SIKLOS hydroxyurea 100-mg and 1000-mg scored tablets; sickle cell anemia, age >=2 years
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.8.
source quality
Oral ibandronate recovered from an official source; mixed RX page still held
The generic-title BONIVA RX page mixes oral descriptive text with injection dosing content. It is not used to create an oral regimen. A separate official oral-tablet summary is now local.
What to reconcileConfirm oral versus intravenous formulation and read the matching local source; do not treat the official addition as recovery of the mixed RX page.
1 source identities and dates
Ibandronate - oral monthly tabletsDailyMed / Aurobindo Pharma Limited | Source revision: Prescribing information revised 03/2026.
Oral ibandronate tablets for treatment or prevention of postmenopausal osteoporosis; not BONIVA injection.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.
product or method difference
BONIVA index name does not establish an oral formulation
The generic BONIVA page retrieved injection content. Only the explicitly identified injection page was imported as new renal guidance; no oral regimen was inferred from the generic-title page.
What to reconcileRead the route on the source card, not only the directory name. Do not transfer the injection monitoring or administration schedule to tablets.
1 source identities and dates
GlobalRPh RX List - BONIVA injectionGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
BONIVA intravenous injection; adult postmenopausal osteoporosis. Not the oral tablet.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.
formulation scope
BONIVA: keep injection and oral records separate
The original injection-specific source is preserved. The new official oral-tablet source is a separate formulation record, not a correction made inside the injection card.
What to reconcileUse the formulation selector to inspect the matching product. The generic-title RX page remains on hold.
1 source identities and dates
GlobalRPh RX List - BONIVA injectionGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
BONIVA intravenous injection; adult postmenopausal osteoporosis. Not the oral tablet.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.
population or indication
Birth-weight neonatal course with a urine-output hold
The dose sequence is specific to premature infants with PDA and uses birth weight. Oliguria at a later scheduled dose leads to withholding, not an invented percentage reduction.
What to reconcileRetain gestational age, birth-weight eligibility, urine output, laboratory recovery and PDA reassessment. This is not adult ibuprofen analgesia guidance.
1 source identities and dates
GlobalRPh RX List - NeoProfenGlobalRPh-hosted RX List | Source revision: March 2021
NeoProfen for clinically significant PDA in premature infants 500-1500 g and no more than 32 weeks gestational age; doses based on birth weight.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.
baseline vs toxicity
Baseline kidney modification does not replace tubular-toxicity surveillance
Protocol-based baseline modifications coexist with the label warning about glomerular and tubular injury, including delayed effects. A baseline reduction is not proof that treatment-emergent injury is controlled.
What to reconcileReview renal trends and tubular/electrolyte findings throughout and after treatment; consider the complete toxicity management instructions rather than continuing from a baseline table alone.
1 source identities and dates
GlobalRPh RX List - IFEXGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Intravenous ifosfamide; product-label renal toxicity/impairment precautions, not a complete oncology regimen.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.
professional protocol difference
Ifosfamide kidney guidance differs between Ewing IE and lymphoma RICE
The two eviQ protocols treat severe kidney impairment differently: the Ewing regimen directs an alternative where the fractionated lymphoma regimen permits a reduction or alternative. The label itself supplies qualitative renal precautions, not these numeric bands.
What to reconcileMatch the malignancy, full chemotherapy protocol, intent, renal measurement and KRT. Different protocols from the same organization are not independent validation or interchangeable prescriptions.
2 source identities and dates
eviQ Ewing sarcoma IE: ifosfamide kidney guidanceeviQ / Cancer Institute NSW | Source revision: Source revision date not established in selected retrieval.
eviQ protocol 3465, Ewing sarcoma IE part of VDC/IE; ifosfamide column only. Not an isolated-agent starting dose.
Read this stored source eviQ lymphoma fractionated RICE: ifosfamide kidney guidanceeviQ / Cancer Institute NSW | Source revision: Source revision date not established in selected retrieval.
eviQ protocol 171, lymphoma fractionated RICE; ifosfamide column only, not the Ewing sarcoma IE protocol.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.
route label identity and dialysis
IV frostbite treatment is not VENTAVIS inhalation
The current BTG label was distinguished from the older Eicos record. Severe-renal intolerance adjustment and dialysis timing do not establish dialysis removal.
What to reconcileConfirm IV product, actual weight, infusion-rate units and hemodynamic tolerance; keep the exposure limitation visible.
2 source identities and dates
GlobalRPh RX List - AURLUMYNGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
AURLUMYN intravenous infusion for severe frostbite in adults to reduce digit-amputation risk; not VENTAVIS inhalation for pulmonary hypertension.
Read this stored source DailyMed / AURLUMYN exact product labelDailyMed / BTG International Inc. | Source revision: 3/2026
AURLUMYN intravenous infusion for severe frostbite in adults to reduce digit-amputation risk; not VENTAVIS inhalation for pulmonary hypertension.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
population or indication
Oral-solution renal caps do not define one oncology starting dose
The source gives a percentage reduction and absolute caps, but the unreduced dose depends on the malignancy and treatment context. The solution has its own concentration.
What to reconcileEstablish the indication-specific dose first; distinguish mg from mL and do not transfer adult limits into a pediatric weight/BSA calculation.
1 source identities and dates
GlobalRPh RX List - IMKELDIGlobalRPh-hosted RX List | Source revision: November 2024
IMKELDI imatinib oral solution, 80 mg/mL; adult renal dose instructions. Indication-specific baseline doses remain necessary.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.
product or method difference
Historical IM scope and clearance-method mismatch
The IM source prints a BSA-indexed threshold but its accompanying formula does not show BSA normalization. The product is distinct from intravenous imipenem combinations.
What to reconcileConfirm product availability, formulation and renal method. Do not use an IV table to fill this historical IM evidence gap.
1 source identities and dates
GlobalRPh RX List - PRIMAXIN IMGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Historical intramuscular imipenem/cilastatin formulation, not PRIMAXIN IV or RECARBRIO. Current availability not verified.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.
monitoring or safety
Sucrose-free IVIG still carries renal-failure precautions
Absence of sucrose does not eliminate kidney injury, including hemolysis-associated injury. Dose/rate minimization and surveillance remain part of the source instructions.
What to reconcileCheck hydration, infusion rate, renal trends and urine output. Do not label sucrose-free immunoglobulin as requiring no renal precautions.
1 source identities and dates
GlobalRPh RX List - PRIVIGENGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
PRIVIGEN intravenous 10% immune globulin; product-specific renal precautions.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.
renal measure ambiguity
CKD-EPI named but BSA denominator omitted in printed units
The source calls its estimate CKD-EPI but prints mL/min. The new card remains unclassified by renal-measure category instead of silently substituting indexed eGFR or absolute clearance.
What to reconcileCheck the exact controlling label and renal measurement before applying the starting-dose band. Include unclassified sources in the finder so this uncertainty does not hide the record.
1 source identities and dates
GlobalRPh RX List - ITOVEBIGlobalRPh-hosted RX List | Source revision: October 2024
Adult oral inavolisib with palbociclib/fulvestrant for the specified breast-cancer indication.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.